sourcing the best research evidence in ophthalmology

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY.

Ophthalmology. 2011 Aug;118(8):1594-602.
Full text | Metrics.

Main finding: Ranibizumab is an effective treatment for macular edema after BRVO.

Purpose: To assess efficacy and safety of intravitreal ranibizumab in patients with macular edema following branch retinal vein occlusion
Study type: Randomized controlled trial
Condition: Branch retinal vein occlusion

Participants: ≥18 yo with centre-involving macular oedema secondary to BRVO, BCVA 20/40-20/400, mean central subfield thickness ≥250 μm

n=397

Intervention:

Group 1: Intravitreal Ranibizumab 0.3mg
Group 2: Intravitreal Ranibizumab 0.5mg
Group 3: Sham

Rescue laser available in all groups if criteriae met.

After 6 months, all patients with BCVA ≤20/40 or central subfield thickness ≥250 μm received ranibizumab.

Outcomes	Time point	RAN 0.3mg	RAN 0.5mg	Sham (RAN after 6mo)
Mean BCVA change (letter)	6 months	+16.6	+18.3	+7.3
	12 months	+16.4	+18.3	+12.1
Gained ≥15 letters in BCVA	6 months	55.2%	61.1%	28.8%
	12 months	56.0%	60.3%	43.9%
BCVA ≥20/40	6 months	67.9%	64.9%	41.7%
Reduction in CFT	6 months	337um	345um	158um

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG.

Ophthalmology. 2010 Jun;117(6):1102-1112.e1.
Full text | Metrics.

Main finding: Ranibizumab is an effective treatment for macular edema after BRVO.

Purpose: To assess efficacy and safety of intravitreal ranibizumab in patients with macular edema following branch retinal vein occlusion
Study type: Randomized controlled trial
Condition: Branch retinal vein occlusion

Participants: ≥18 yo with centre-involving macular oedema secondary to BRVO, BCVA 20/40-20/400, mean central subfield thickness ≥250 μm

Intervention:

Group 1: Intravitreal Ranibizumab 0.3mg
Group 2: Intravitreal Ranibizumab 0.5mg
Group 3: Sham

Rescue laser available in all groups if criteriae met.

After 6 months, all patients with BCVA ≤20/40 or central subfield thickness ≥250 μm received ranibizumab.

Outcomes	Time point	RAN 0.3mg	RAN 0.5mg	Sham (RAN after 6mo)
Mean BCVA change (letter)	6 months	+16.6	+18.3	+7.3
	12 months	+16.4	+18.3	+12.1
Gained ≥15 letters in BCVA	6 months	55.2%	61.1%	28.8%
	12 months	56.0%	60.3%	43.9%
BCVA ≥20/40	6 months	67.9%	64.9%	41.7%
Reduction in CFT	6 months	337um	345um	158um

Share This Article :

Updated on March 7th, 2022